» Articles » PMID: 30986904

Human Multilineage 3D Spheroids As a Model of Liver Steatosis and Fibrosis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Apr 17
PMID 30986904
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in western countries. Despite the high prevalence of NAFLD, the underlying biology of the disease progression is not clear, and there are no approved drugs to treat non-alcoholic steatohepatitis (NASH), the most advanced form of the disease. Thus, there is an urgent need for developing advanced in vitro human cellular systems to study disease mechanisms and drug responses. We attempted to create an organoid system genetically predisposed to NAFLD and to induce steatosis and fibrosis in it by adding free fatty acids. We used multilineage 3D spheroids composed by hepatocytes (HepG2) and hepatic stellate cells (LX-2) with a physiological ratio (24:1). HepG2 and LX-2 cells are homozygotes for the I148M sequence variant, the strongest genetic determinant of NAFLD. We demonstrate that hepatic stellate cells facilitate the compactness of 3D spheroids. Then, we show that the spheroids develop accumulations of fat and collagen upon exposure to free fatty acids. Finally, this accumulation was rescued by incubating spheroids with liraglutide or elafibranor, drugs that are in clinical trials for the treatment of NASH. In conclusion, we have established a simple, easy to handle, in vitro model of genetically induced NAFLD consisting of multilineage 3D spheroids. This tool may be used to understand molecular mechanisms involved in the early stages of fibrogenesis induced by lipid accumulation. Moreover, it may be used to identify new compounds to treat NASH using high-throughput drug screening.

Citing Articles

Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model.

Chu X, Wang X, Feng K, Bi Y, Xin Y, Liu S Lipids Health Dis. 2025; 24(1):55.

PMID: 39962463 PMC: 11831825. DOI: 10.1186/s12944-025-02483-z.


Advances in liver organoids: replicating hepatic complexity for toxicity assessment and disease modeling.

Shao W, Xu H, Zeng K, Ye M, Pei R, Wang K Stem Cell Res Ther. 2025; 16(1):27.

PMID: 39865320 PMC: 11771052. DOI: 10.1186/s13287-025-04139-2.


Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention.

Youhanna S, Kemas A, Wright S, Zhong Y, Klumpp B, Klein K Adv Sci (Weinh). 2024; 12(3):e2407572.

PMID: 39605182 PMC: 11744578. DOI: 10.1002/advs.202407572.


A Review on the Protecting Effects and Molecular Mechanisms of Berries Against a Silent Public Health Concern: Non-Alcoholic Fatty Liver Disease.

Sharma A, Lee H Antioxidants (Basel). 2024; 13(11).

PMID: 39594531 PMC: 11590959. DOI: 10.3390/antiox13111389.


Mouse Models for the Study of Liver Fibrosis Regression and .

Schonke M, Rensen P J Clin Transl Hepatol. 2024; 12(11):930-938.

PMID: 39544245 PMC: 11557367. DOI: 10.14218/JCTH.2024.00212.


References
1.
Xu N, Hurtig M, Zhang X, Ye Q, Nilsson-Ehle P . Transforming growth factor-beta down-regulates apolipoprotein M in HepG2 cells. Biochim Biophys Acta. 2004; 1683(1-3):33-7. DOI: 10.1016/j.bbalip.2004.04.001. View

2.
Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M . Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis. 2005; 37(5):349-56. DOI: 10.1016/j.dld.2004.11.009. View

3.
Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

4.
Adiels M, Taskinen M, Packard C, Caslake M, Soro-Paavonen A, Westerbacka J . Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 2006; 49(4):755-65. DOI: 10.1007/s00125-005-0125-z. View

5.
van de Bovenkamp M, Groothuis G, Meijer D, Olinga P . Liver fibrosis in vitro: cell culture models and precision-cut liver slices. Toxicol In Vitro. 2007; 21(4):545-57. DOI: 10.1016/j.tiv.2006.12.009. View